POSITION	AA	Category	Comment
40	F	NRTI	E40F is a non-polymorphic accessory mutation selected by AZT and d4T. It usually occurs in combination with M41L, L210W and T215Y. In this context it is associated with reduced susceptibility to each of the NRTIs.
41	I	Other	M41I is usually an artifact resulting from APOBEC3G-mediated hypermutation.
41	L	NRTI	M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.
44	AD	NRTI	E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs.
62	V	NRTI	A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic.
65	E	NRTI	K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT. K65E is an extremely rare NRTI-selected mutation with markedly reduced replication fitness.
65	N	NRTI	K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT. K65N is a rare mutation with similar but less pronounced effects on NRTI susceptibility than K65R.
65	R	NRTI	K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT.
67	Deletion	NRTI	Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex.
67	GESTH	NRTI	D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs.
67	N	NRTI	D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF.
68	Deletion	NRTI	Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex. Deletions at codon 68 are extremely rare and less well characterized.
68	G	Other	S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R.
69	Deletion	NRTI	Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex.
69	D	NRTI	T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T.
69	G	NRTI	T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations.
69	N	Other	T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT.
69	SAIE	Other	T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied.
69	Insertion	NRTI	Amino acid insertions between codons 67 and 70 are by convention assigned to codon 69. Together with TAMs, they are associated with high-level resistance to AZT, d4T, ddI, ABC and TDF and intermediate to 3TC and FTC.
70	Deletion	NRTI	Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex.
70	EG	NRTI	K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT.
70	QNST	NRTI	K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G.
70	R	NRTI	K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF.
74	VI	NRTI	L74V/I cause high-level resistance to ddI and intermediate resistance to ABC.
75	I	NRTI	V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain.
75	M	NRTI	V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance.
75	SA	NRTI	V75S/A are non-polymorphic mutations that appear to reduce susceptibility to d4T and ddI.
75	T	NRTI	V75T causes high-level d4T resistance and intermediate ddI resistance.
77	L	NRTI	F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain.
115	F	NRTI	Y115F causes intermediate resistance to ABC and low-level resistance to TDF.
116	Y	NRTI	F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M.
118	I	Other	V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs.
151	L	NRTI	Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M.
151	M	NRTI	Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC.
184	VI	NRTI	M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.
210	W	NRTI	L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF.
215	F	NRTI	T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.
215	SCDEIVALN	NRTI	T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F.
215	Y	NRTI	T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.
219	NR	NRTI	K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs.
219	QE	NRTI	K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T.
219	W	NRTI	K219W is an uncommon NRTI-selected mutation.
90	I	Other	V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a low weight in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility.
98	G	NNRTI	A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.
100	I	NNRTI	L100I is a non-polymorphic mutation that usually occurs in combination with K103N. It is associated with high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a high weight in the Tibotec ETR genotypic susceptibility score.
100	V	NNRTI	L100I is a non-polymorphic mutation that usually occurs with K103N. It is associated with high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, ETR, and RPV.
101	E	NNRTI	K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, and low-level resistance to EFV and ETR. It has a low weight in the Tibotec ETR genotypic susceptibility score.
101	H	NNRTI	K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a low weight in the Tibotec ETR genotypic susceptibility score.
101	NAT	Other	K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance.
101	P	NNRTI	K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a high weight in the Tibotec ETR genotypic susceptibility score.
101	Q	Other	K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance.
103	EQ	NNRTI	K103E/Q are rare mutations that have not been associated with reduced NNRTI susceptibility.
103	H	NNRTI	K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.
103	N	NNRTI	K103N is a non-polymorphic mutation that causes high-level resistance to NVP and EFV.
103	R	Other	K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it causes intermediate resistance to EFV and NVP.
103	S	NNRTI	K103S is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, patients with K103S may be likely to have once had K103N.
103	T	NNRTI	K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.
106	A	NNRTI	V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV.
106	I	Other	V106I is a polymorphic NNRTI-selected accessory mutation. It has a low weight in the Tibotec ETR genotypic susceptibility score. It has minimal, if any, effect on NNRTI susceptibility.
106	M	NNRTI	V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV.
108	I	NNRTI	V108I is a relatively non-polymorphic accessory mutation selected in patients receiving NVP, EFV and ETR. It causes low-level resistance to NVP and potentially low-level resistance to EFV. It does not appear to reduce susceptibility to ETR or RPV.
132	ML	Other	I132M is an extremely rare non-polymorphic mutation associated with uncertain amount of reduced NVP and EFV susceptibility. I132L is a more common, non-polymorphic NNRTI-selected mutation that has not been well studied.
138	A	NNRTI	E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It confers a borderline low-level reduction in RPV susceptibility. It has a low weight in the Tibotec ETR genotypic susceptibility score.
138	K	NNRTI	E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but minimal, if any, cross-resistance to NVP and EFV.
138	QG	NNRTI	E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. Preliminary data suggest that E138Q/G are associated with 2 to 3-fold reduced susceptibility to each of the NNRTIs.
138	R	NNRTI	E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It confers a borderline low-level reduction in RPV susceptibility.
179	DE	NNRTI	V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a low weight in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.
179	F	NNRTI	V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. However, the combination of V179F and Y181C is associated with high-level ETR and RPV resistance. It has a low weight in the Tibotec ETR genotypic susceptibility score.
179	I	Other	V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility.
179	L	NNRTI	V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.
179	T	NNRTI	V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a low weight in the Tibotec ETR genotypic susceptibility score.
181	C	NNRTI	Y181C is a non-polymorphic mutation selected in patients receiving each of the NNRTIs. It causes high-level reduction in NVP susceptibility, intermediate-level reduction in RPV and ETR susceptibility, and low-level reduction in EFV susceptibility. Y181C has a high weight in the Tibotec ETR genotypic susceptibility score.
181	FSG	NNRTI	Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.
181	IV	NNRTI	Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level reductions in NVP, ETR, and RPV susceptibility. They each have a high weight in the Tibotec ETR genotypic susceptibility score.
188	C	NNRTI	Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.
188	F	NNRTI	Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.
188	H	NNRTI	Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about intermediate-level reductions in NVP and EFV susceptibility.
188	L	NNRTI	Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, and RPV and potentially low-level resistance to ETR.
190	A	NNRTI	G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a low weight in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations.
190	CTV	NNRTI	G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR and RPV susceptibility are not known.
190	EQ	NNRTI	G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance and probable intermediate / high-level resistance to ETR and RPV.
190	S	NNRTI	G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a low weight in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations.
221	Y	NNRTI	H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.
225	H	NNRTI	P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces EFV susceptibility.
227	C	NNRTI	F227C is an extremely rare non-polymorphic mutation selected by ETR and RPV. It usually occurs in combination with other NNRTI-resistance mutations and in this context it is associated with high-level resistance to each of the NNRTIs.
227	L	NNRTI	F227L is a non-polymorphic mutation that usually occurs in combination with V106A. In this context it is associated with high-level resistance to NVP and EFV.
230	I	NNRTI	M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious.
230	L	NNRTI	M230L is an uncommon non-polymorphic mutation selected in patients receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.
236	L	NNRTI	P236L is a non-polymorphic mutation that causes high-level DLV resistance but does not reduce susceptibility to any other NNRTIs.
238	R	Other	K238R is a common polymorphism that does not reduce NNRTI susceptibility.
238	TN	NNRTI	K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. Alone it confers low/intermediate reductions in NVP and EFV susceptibility. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effect on NNRTI susceptibility.
318	F	NNRTI	Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance.
348	I	NNRTI	N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it confers low-level reductions in AZT and NVP susceptibility.
